Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 6, 2013, Pages 711-715

  Duong, Vu H ^a   Lin, Karen ^b   Reljic, Tea ^c   Kumar, Ambuj ^c   Al Ali, Najla H ^b   Lancet, Jeffrey E ^b   List, Alan F ^b   Komrokji, Rami S ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Azacitidine failure; Azanucleosides; Decitabine; Higher risk; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DATA BASE; DISEASE COURSE; FEMALE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

AZACITIDINE FAILURE; AZANUCLEOSIDES; DECITABINE; HIGHER RISK; MDS;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84888008620     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.07.007     Document Type: Article

References (18)

1. J.M. Bennett, and R.S. Komrokji The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment Hematology 10 suppl 1 2005 258 269
2. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079
3. H. Kantarjian, S. O'Brien, and F. Ravandi Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 2008 1351 1361
4. L. Malcovati, U. Germing, and A. Kuendgen Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
5. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
6. M. Lubbert, S. Suciu, and L. Baila Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 2011 1987 1996
7. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2002 2429
8. P. Fenaux, G.J. Mufti, and E. Hellström-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562
9. E. Jabbour, G. Garcia-Manero, and N. Batty Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 2010 3830 3834
10. T. Prébet, S.D. Gore, and B. Esterni Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure J Clin Oncol 29 2011 3322 3327
11. J.W. Vardiman, J. Thiele, and D.A. Arber The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
12. B.D. Cheson, P.L. Greenberg, and J.M. Bennett Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2006 419
13. T. Prebet, S. Thepot, and S.D. Gore Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure Haematologica 98 2013 e18 e19
14. G. Borthakur, S.E. Ahdab, and F. Ravandi Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine Leuk Lymphoma 49 2008 690 695
15. T. Prebet, A. Charbonnier, and V. Gelsi-Boyer Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure Leuk Lymphoma 54 2013 1538 1540
16. M.A. Sekeres, A.F. List, and D. Cuthbertson Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes J Clin Oncol 28 2010 2253 2258
17. M.A. Sekeres, C. O'Keefe, and A.F. List Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes Am J Hematol 86 2011 102 103
18. M.A. Sekeres, R.V. Tiu, and R. Komrokji Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes Blood 120 2012 4945 4951